Long-term outcomes in patients after discontinuation of PD1/PDL1 inhibitors.

2018 
e15086Background: PD1/PDL1inhibitors have been approved for several advanced or metastatic malignancies with improvement in both progression free and overall survival. Yet, there is a paucity of da...
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    2
    Citations
    NaN
    KQI
    []